Friday, October 31, 2014

Roth starts CorMedix at buy

Roth starts CorMedix at buy

July 24, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of CorMedix (NYSE:CRMD) with a “buy” rating and $3 price target. The stock closed at $1.94 on Wednesday. “The impetus for our buy rating is the potential of the company’s Neutrolin compound to drive revenues and ultimately profits,” writes analyst Scott Henry. Neutrolin is approved in Europe and […]

Roth starts Kindred Biosciences at buy

Roth starts Kindred Biosciences at buy

February 4, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Kindred Biosciences (NYSE:KIN) with a “buy” rating and $20 price target. The stock closed at $15.41 on Monday.  Kindred is focused on developing and marketing new drugs for dogs, horses, and cats.  “The impetus for our buy rating is a low-risk animal health pipeline that could result […]

Roth ups Chelsea Therapeutics price target

Roth ups Chelsea Therapeutics price target

January 17, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” Chelsea Therapeutics (NASDAQ:CHTP) to $7 from $4, reflecting a positive FDA panel ruling for its Northera drug candidate. The stock closed at $4.70 on Thursday. On Tuesday, the FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 16-1 to recommend approval of Northera for […]

Roth starts ANI Pharma at buy

Roth starts ANI Pharma at buy

January 7, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of ANI Pharmaceuticals (NASDAQ:ANIP) with a “buy” rating and $27 price target. The stock closed at $19 on Monday. “The impetus for our buy rating is continued earnings growth based on strong current revenue drivers, capacity for expansion, and a pipeline (internal and external) ready to fill that […]

Roth ups Catalyst Pharma price target

Roth ups Catalyst Pharma price target

October 16, 2013 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target on “buy-rated” Catalyst Pharmaceutical Partners (NASDAQ:CPRX) to $3.75 from $2.75, after the company completed a recent financing and a data monitoring committee recommended that its Phase 3 Firdapse trial continue as planned. Shares of Catalyst Pharma closed at $2.70 on Tuesday. “This [price target] increase reflects […]

Tonix developing treatment overlap for fibromyalgia and PTSD

Tonix developing treatment overlap for fibromyalgia and PTSD

October 8, 2013 by · Leave a Comment 

Tweet After initiating enrollment of a Phase 2b/3 clinical trial of TNX-102 SL in fibromyalgia (FM) patients earlier this month, Tonix Pharmaceuticals Holding (NASDAQ:TNXP) is now setting its sights on a Phase 2a trial of its drug candidate as a treatment for post-traumatic stress disorder (PTSD). “About 50% of FM and PTSD patients meet the […]

Roth starts IGI Labs at buy

Roth starts IGI Labs at buy

August 7, 2013 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of IGI Laboratories (NYSE MKT:IG) with a “buy” rating and 12-month price target of $3.50, saying the impetus for the rating is “expectations for the company’s internal proprietary generic pipeline to come to fruition and drive sustainable earnings profitability.” Shares of IGI closed at $1.49 on Tuesday. Analyst […]

Roth starts Alexza at buy

Roth starts Alexza at buy

December 4, 2012 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Alexza Pharmaceuticals (NASDAQ:ALXA) with a “buy” rating and $10 price target, citing expectations for positive regulatory updates for Adusave in the U.S. and EU. The stock closed at $5.47 on Monday. Alexza is a drug delivery company with late-stage Adusave for the treatment of institutional agitation. “We […]

Roth starts Trimel at buy

Roth starts Trimel at buy

October 16, 2012 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Trimel Pharmaceuticals (TSX:TRL) with a “buy” rating and 12-month price target of $3, citing expectations for positive CompleoTRT data and a potential marketing partnership. The stock closed at $1.59 on Monday. CompleoTRT is a testosterone replacement for men. The testosterone market is already a $2-billion market, and […]

Roth ups Somaxon price target

Roth ups Somaxon price target

August 8, 2012 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target on Somaxon Pharmaceuticals (NASDAQ:SOMX) to 55 cents from 50 cents, saying the company recently completed multiple milestones that should reduce the chance for bankruptcy, and lift the company’s value, either via sale or stand-alone entity. Analyst Scott Henry highlights recently settled patent litigation for the approved […]

Next Page »

Email Newsletters with Constant Contact
Google+